Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
Veru (VERU)
NASDAQ:VERU
Veru (VERU) Stock Price & Analysis
1,672 Followers
VERU Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.36 - $1.92
Previous Close$1.42
Volume1.30M
Average Volume (3M)2.48M
Market Cap
$203.47M
Enterprise Value$202.91M
Total Cash (Recent Filing)$9.63M
Total Debt (Recent Filing)$4.67M
Price to Earnings (P/E)-1.9
Beta0.18
Next Earnings
May 09, 2024EPS Estimate
-$0.06Last Dividend Ex-Date
Apr 28, 2014Dividend YieldN/A
Share Statistics
EPS (TTM)-0.76
Shares Outstanding146,381,186
10 Day Avg. Volume5,856,798
30 Day Avg. Volume2,481,245
Standard Deviation0.38
R-Squared0.00089
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)15.61
Price to Sales (P/S)82.89
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue14.71
Enterprise Value/Gross Profit26.82
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
$3.33Price Target Upside139.57% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering3
Veru News
PremiumPress Releases
Veru Reschedules Annual Meeting of Shareholders
Ownership Overview
16.29%
Insiders
5.09% Mutual Funds
3.51% Other Institutional Investors
75.11% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
VERU FAQ
What was Veru’s price range in the past 12 months?
Veru lowest stock price was $0.36 and its highest was $1.92 in the past 12 months.
What is Veru’s market cap?
Currently, no data Available
When is Veru’s upcoming earnings report date?
Veru’s upcoming earnings report date is May 09, 2024 which is in 19 days.
How were Veru’s earnings last quarter?
Veru released its earnings results on Feb 08, 2024. The company reported -$0.08 earnings per share for the quarter, beating the consensus estimate of -$0.12 by $0.04.
Is Veru overvalued?
According to Wall Street analysts Veru’s price is currently Undervalued.
Does Veru pay dividends?
Veru pays a Quarterly dividend of $0.07 which represents an annual dividend yield of N/A. See more information on Veru dividends here
What is Veru’s EPS estimate?
Veru’s EPS estimate is -$0.06.
How many shares outstanding does Veru have?
Veru has 146,381,180 shares outstanding.
What happened to Veru’s price movement after its last earnings report?
Veru reported an EPS of -$0.08 in its last earnings report, beating expectations of -$0.12. Following the earnings report the stock price went down -6.818%.
Which hedge fund is a major shareholder of Veru?
Among the largest hedge funds holding Veru’s share is Perceptive Advisors LLC. It holds Veru’s shares valued at 4M.
---
Veru Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$3.33 (139.57% Upside)
$3.33 (139.57% Upside)
Blogger Sentiment
Neutral
VERU Sentiment 50%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 4.5M Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Positive
Last 7 Days ▼ 2.1%
Last 30 Days ▲ 4.9%
Last 30 Days ▲ 4.9%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Positive
20 days / 200 days
Momentum
11.53%
12-Months-Change
Fundamentals
Return on Equity
-128.27%
Trailing 12-Months
Asset Growth
-22.37%
Trailing 12-Months
Company Description
Veru
Veru, Inc. is an oncology and urology biopharmaceutical company. It develops medicines for prostate cancer treatment and prostate cancer supportive care as well as urology specialty pharmaceuticals. Its oncology drug candidates includes VERU-111, an oral alpha and beta tubulin inhibitor, which is in a phase 1b/2 study for the treatment of metastatic castration resistant prostate cancer; Zuclomiphene citrate, which is in a phase 2 clinical trial for the treatment of hot flashes in men undergoing prostate cancer hormonal therapies; and VERU-100, a long-acting GnRH antagonist 3 month subcutaneous depot, planned phase 2 clinical trial for the treatment of hormone sensitive advanced prostate cancer. The company's urology specialty pharmaceutical drug candidate is TADFIN, a tadalafil and finasteride combination oral capsule, for the treatment of men with benign prostatic hyperplasia. Its commercial products include the FC2 Female/Internal condom for prevention of pregnancy and sexually transmitted infections and PREBOOST 4% benzocaine wipes for the prevention of premature ejaculation marketed as Roman Swipes by getroman.com. The company was founded by William R. Gargiulo Jr. and O.B. Parrish in 1996 and is headquartered in Miami, FL.
---
VERU Earnings Call
Q1 2024
0:00 / 0:00
---
VERU Stock 12 Months Forecast
Average Price Target
$3.33
▲(139.57% Upside)
Technical Analysis
Best Analysts Covering VERU
1 Year
1 Year Success Rate
13/29 ratings generated profit
1 Year Average Return
+21.48%
assigned a buy rating 5 days ago
Copying Leland Gershell's trades and holding each position for 1 Year would result in 44.83% of your transactions generating a profit, with an average return of +21.48% per trade.
---